Innate Pharma primarily targets severe oncological diseases and hematological malignancies with high unmet medical needs. Its clinical and preclinical development pipelines focus extensively on various cancers, including advanced solid tumors (such as non-small cell lung cancer), cutaneous T-cell lymphomas, peripheral T-cell lymphomas, and other forms of leukemia and lymphoma, utilizing specialized immunotherapies designed to modulate the tumor microenvironment and activate patient immune defenses.